About Us

ZIVO has partnered with the Arizona Center for Algae Technology and Innovation (AzCATI) for the Company's research and development initiatives. Here, an AzCATI research scientist prepare a sample for analysis.

Our Story

Delivering a novel, plant-based protein source and supporting healthy metabolic function has been the primary focus of this Company’s R&D efforts. The work to date has yielded promising developments in several areas of nutrition, specifically dietary supplement ingredients and functional food ingredients. The Company has commenced study and development that target the following applications:

  • Sustainable, non-GMO, antibiotic-free, non-animal protein source with optimal amino acid profile

  • Support for optimal skeleto-muscular health during aging, exertion, and strenuous exercise

  • Support healthy immune response

  • Healthy metabolic function

In this new phase of the Company’s history, ZIVO Bioscience is working diligently to develop proprietary and patented bioactive compounds to be used as ingredients in foods, supplements, and possibly medicines. This also involves the development of high-volume production techniques, stabilization processes, and ingredient-oriented technologies that will preserve the beneficial effects of these natural substances once introduced into foodstuffs or liquids.

In addition to ZIVO Bioscience’s nutrition-focused R&D initiatives, the Company has also developed a breakthrough wellness testing platform for human and animal use. Explore WellMetris for more information.

Mission & Objectives

The Company strives to fully harness the benefits of its natural nutritive and bioactive products, make them affordable and readily available in a useful and convenient form. We are dedicated to finding innovative, cost-effective techniques and technologies that help the greatest number of people access the widest range of products and applications to serve their nutrition and health needs or those of animals in their care.

ZIVO Bioscience is committed to the ideal of promoting health optimized nutrition and naturally occurring bioactive ingredients. These active ingredients are produced and processed to obtain the highest possible nutritive and health benefit. Every step of the process is monitored and measured by an exacting protocol and dedicated professionals. Customers can be assured of consistent and reliable nutrition, purity, and sample integrity.

As the nutrition and supplement markets mature and consumers become better informed, government oversight increases accordingly. ZIVO Bioscience welcomes these developments. The Company approaches food science and nutrition as legitimate fields of scientific inquiry and discovery on par with the physical sciences and medical arts.

As a new source of plant-based protein and micronutrients, the proprietary ZIVO algae strain will initially find its application as a human dietary supplement, a source of high quality, non-animal nutrition, animal supplement and livestock feed additive, boosting productivity and overall health.

ZIVO Bioscience is not a household name. However, its products and ingredients may someday find their way into every home as a sports drink, a tasty yet healthful snack, a smart pet treat or a more traditional human supplement – health benefits that become a part of everyday life for every life.

Research & Development Policy Statement

ZIVO Bioscience is committed to rigorous scientific testing, peer review, and regulatory compliance. No product or ingredient is developed without a clear-cut purpose or application. No product or ingredient is made available until independent research and testing has verified efficacy and safety to the appropriate standard for that product category.

The Company extensively tests and retests its products during the development stages and throughout the product lifespan. Each product is carefully monitored and measured to ensure integrity, activity, and safety.

An array of algae cultures in various stages of growth – courtesy AzCATI


In 2012, ZIVO Bioscience, Inc. transformed it business model to a licensor of internally developed intellectual property, to include its proprietary algae cultures, extracts and derivatives thereof, in addition to IP secured through strategic acquisitions. In order to maximize the value and earning power of such licenses, the Company is engaged in continuous research and development to provide its licensees with the scientific and technical support needed to move into production and distribution.

The management team and advisors work together to develop viable science and viable business models with available resources, looking for the best near-term opportunities without compromising safety or efficacy.


Andrew A. Dahl
President / Chief Executive Officer

Mr. Dahl was formerly principal consultant and managing director of Great Northern & Reserve Partners, LLC, a marketing strategy and business planning consultancy focused on the biomed and biotech sectors, since 2005. For the previous 20 years, Mr. Dahl served as President of Dawber & Company, Inc., one of the largest independent marketing & consulting firms in the Midwest, with an extensive Fortune 500 client roster that included GM, Ford, Northwest, Xerox, AT&T and Compuware, among others. He attended the College for Creative Studies and Wayne State University. Mr. Dahl holds three US patents for interactive multimedia and is a named inventor in one recent biotech patent and several biomed patent applications.

Philip M. Rice II
Chief Financial Officer

Philip Rice operates a financial consultancy under the aegis of Legacy Results, LLC. Prior to 2001, he served as COO and director of Stahl’s Inc. ($90 million multi-national company), CFO of Gallagher-Kaiser Corp. ($110 million 1999 revenues) and President/CFO of Speedy International, Inc., an international print franchisor. Mr. Rice began his professional career at Deloitte & Touche where he became a Certified Public Accountant in 1979 working on international assignments. He is a member of the Michigan Association of CPAs and the American Institute of CPAs, and has served on the Board of Directors of the Detroit Regional Chamber of Commerce. Mr. Rice earned a Bachelor of Business Administration from the University of Cincinnati.

Dr. Scott Freeman
Chief Science Officer

Dr. Freeman is a drug development consultant for biotechnology and pharmaceutical companies. Dr. Freeman served as Vice President of Clinical Development at Onyx Pharmaceutical (2001-2006) and was head of both clinical development and operations, which executed the clinical trials for renal cell, melanoma, liver, lung, and colorectal cancer. The Phase 1, 2, and 3 trials in kidney and liver cancer were successfully performed and led to NDA approval of Nexavar. As Clinical Project Director at Schering-Plough Research Institute (1998-2001), his clinical projects included Phase 1, 2, and 3 trials for an anti-estrogen program, a breast cancer treatment, and a P53 gene therapy program. He was Associate Professor at Tulane University (1992-1998) and also served as the Medical Director for the Tulane Blood Center. Dr. Freeman has published sixty-four scientific papers. Dr. Freeman earned his B.A. from the University of Colorado in 1978 and received his MD from the University of Nevada in 1983. Dr. Freeman completed an internship and residency at the University of Minnesota in pediatrics and clinical pathology, respectively.

Dr. Amy Steffek
Director, Research & Development

Amy Elizabeth Steffek, Ph.D., serves as the Company’s Director of Research & Development. She earned a Ph.D. in Neuroscience from the University of Michigan in 2007 and completed fellowships in Translational Medicine and Neuroendocrinology at the University of Michigan in 2010. Dr. Steffek has over 13 years of scientific research experience spanning neurology, cardiology, oncology, psychiatry, and endocrinology. As a consultant, she has helped companies develop pharmaceutical products, medical devices, medical IT products, and pre-clinical research services.

Board of Directors

Philip M. Rice II
Chairman since 2012

Resume presented in previous section.

John B. Payne
Director since 2013

Mr. Payne brings more than 30 years’ experience in the global animal health industry to the ZIVO board of directors. Mr. Payne is a board member and officer of the American Humane Association and CEO of Compassion First Pet Hospitals, having previously served as President and CEO of Banfield Pet Hospitals, and a leadership team member for Mars Global PetCare. Mr. Payne also served as President and General Manager of Bayer Healthcare's North American Animal Health Division. He has been honored for his commitment to bringing “human quality” medicine and healthcare to pets, and has gained worldwide recognition for his achievements.

Nola E. Masterson
Director since September 2014

Ms. Masterson has an extensive and well-regarded track record in the biotech industry, and has 33 years of experience in the life science industry. Ms. Masterson is the Chair Emeritus of the Bay Bio Institute, a 501(c)3 affiliate of BayBio. Since 1982, she has been the Chief Executive Officer of Science Futures Inc., an investment and advisory firm, and is currently Managing Member and General Partner of Science Futures LLC, I and II, which are venture capital funds invested in life science funds and companies. She received her Masters’ degree in Biological Sciences from George Washington University, and continued Ph.D. coursework at the University of Florida.

Robert O. Rondeau, Jr.
Director since March 2016

Mr. Rondeau brings years of experience in finance and lending to the Board of Directors. As chief executive officer of PRZ, LLC, a financing company Mr. Rondeau has focused on inventory financing, retail financing and leasing, a position he has held since 2013. Mr. Rondeau is also the chief executive officer of Bran Financial, a credit card processing company, a position he has held since 2010. Prior to that, Mr. Rondeau was an executive director of Flagstar Bank, focusing on commercial, consumer and warehouse lending from 2004 through 2009, and President of Flagstar Bank’s title insurance subsidiary. Mr. Rondeau received a Bachelor of Arts degree from Northwestern University and an Executive M.B.A. from Michigan State University.

Christopher Maggiore
Director since 2013

Mr. Maggiore was appointed to the Board of Directors on August 28, 2013. He has a successful track record in entrepreneurship, with over 25 years of experience in the areas of real estate development and building and management of businesses. Mr. Maggiore currently owns and manages a portfolio of diverse businesses and investments.